Download PDF
Thromb Haemost 1988; 60(01): 021-024
DOI: 10.1055/s-0038-1647627
Original Article
Schattauer GmbH Stuttgart

Platelet Function and Plasma Fibrinogen and their Relations to Gender, Smoking Habits, Obesity and Beta-Blocker Treatment in Young Survivors of Myocardial Infarction

Ulf Berglund
The Department of Internal Medicine, University Hospital, Linköping, Sweden
,
Lars Wallentin
The Department of Internal Medicine, University Hospital, Linköping, Sweden
,
Henning von Schenck
*   The Department of Clinical Chemistry, University Hospital, Linköping, Sweden
› Author Affiliations
Further Information

Publication History

Received 07 September 1987

Accepted after revision 16 March 1988

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Seventy-three (58 men and 15 women) survivors of myocardial infarction below 45 years of age and 73 healthy matched controls were investigated regarding in vitro platelet aggregability to ADP and collagen, platelet sensitivity to prostacyclin and plasma levels of beta-thromboglobulin, platelet factor 4 and fibrinogen. The patients, studied 3-6 months after the acute event, had a reduced platelet sensitivity to prostacyclin. They did not differ from the controls regarding the other platelet function tests. Females had higher platelet reactivity than men. Smoking, obesity or beta- blocker treatment did not influence platelet function. The patients had higher fibrinogen levels than the controls. Gender did not influence, while smoking and obesity increased plasma fibrinogen. Patients on beta-blockade had lower fibrinogen levels than patients without this therapy. The high fibrinogen level and the low platelet sensitivity to prostacyclin might indicate an increased thrombotic liability in young myocardial infarction patients.

Key words

Platelet function - Platelet sensitivity to prostacyclin - Fibrinogen - Myocardial infarction - Beta-blocker treatment
 

  • References

  • 1 Wood MA De, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
    CrossrefPubMedGoogle Scholar
  • 2 Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 1985; 53: 363-373
    CrossrefPubMedGoogle Scholar
  • 3 Maseri A, Chierchia S, Davies G. Pathophysiology of coronary occlusion in acute infarction. Circulation 1986; 73: 233-239
    CrossrefPubMedGoogle Scholar
  • 4 Roskamm H, Gohlke H, Sturzenhofecker P, Droste C, Thomas H, Samek L, Schnellbacher K, Betz P. Der Herzinfarkt im jugendlichen Alter (unter 40 Jahren): Koronarmorphologie, Langzeitprognose der Erkrankung und Progression der Koronargefäßsklerose. Z Kardiol 1983; 72: 1-11
    PubMedGoogle Scholar
  • 5 Hoit BD, Gilpin EA, Henning H, Maisei AA, Dittrich H, Carlisle J, Ross Jr J. Myocardial infarction in young patients: an analysis by age subsets. Circulation 1986; 74: 712-721
    CrossrefPubMedGoogle Scholar
  • 6 Wei JY, Bulkley BH. Myocardial infarction before age 36 years in women: Predominance of apparent nonatherosclerotic events. Am Heart J 1982; 104: 561-566
    CrossrefPubMedGoogle Scholar
  • 7 Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, De Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66
    CrossrefPubMedGoogle Scholar
  • 8 Hamsten A, Svensson J, Walldius G, Szamosi A, De Faire U. Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction. Am Heart J 1985; 110: 1154-1160
    CrossrefPubMedGoogle Scholar
  • 9 Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation 1981; 63: 546-551
    CrossrefPubMedGoogle Scholar
  • 10 Vilen L, Johansson S, Kutti J, Cronberg S, Vedin A, Wilhelmsson C. ADP-induced platelet aggregation in young female survivors of acute myocardial infarctioin and their female controls. Acta Med Scand 1985; 217: 9-13
    PubMedGoogle Scholar
  • 11 Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979; 59: 607-609
    CrossrefPubMedGoogle Scholar
  • 12 Berglund U, Von Schenck H, Wallentin L. Effects of Ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemostas 1985; 54: 808-812
    PubMedGoogle Scholar
  • 13 Sinzinger H, Schernthaner G, Kaliman J. Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris. Prosta-glandins 1981; 22: 773-781
    CrossrefPubMedGoogle Scholar
  • 14 Ludlam CA, Cash JD. Studies on the liberation of beta-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
    CrossrefPubMedGoogle Scholar
  • 15 Desvignes P, Bonnet P. Direct determination of plasma fibrinogen levels by heat precipitation. A comparison of the technique thrombin clottable fibrinogen with spectophotometry and radial immunodiffusion Clin Chim Acta 1981; 110: 9-17
    CrossrefPubMedGoogle Scholar
  • 16 Swahn E, Wallentin L. Platelet reactivity in unstable coronary artery disease. Thromb Haemostas 1987; 57: 302-305
    PubMedGoogle Scholar
  • 17 Mueller HS, Rao PS, Greenberg MA, Buttrick PM, Sussman II, Levite HA, Grose RM, Perez-Davila V, Strain JE, Spaet TH. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985; 72: 1336-1345
    CrossrefPubMedGoogle Scholar
  • 18 Sorkin RP, Tokarsky JM, Huber-Smith MJ, Steiger JF, McCann DS. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982; 104: 1255-1261
    CrossrefPubMedGoogle Scholar
  • 19 Buttrick PM, Forscher CA, Sussman II, Mueller HS. Subaggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation. Am Heart J 1985; 109: 1258-1264
    CrossrefPubMedGoogle Scholar
  • 20 Neri Serneri GG, Modesti PA, Fortini A, Abbate R, Lombardi A, Gensini GF. Reduction in prostacyclin platelet receptors in spontaneous angina. Lancet 1984; 2: 838-841
    PubMedGoogle Scholar
  • 21 Nadler JL, Velasco JS, Horton R. Cigarette smoking inhibits prostacyclin formation. Lancet 1983; 1: 1248-1250
    PubMedGoogle Scholar
  • 22 Sinzinger H, Kefalides A. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostacyclin. Lancet 1982; 2: 392-393
    PubMedGoogle Scholar
  • 23 Levine PH. An acute effect of cigarette smoking on platelet function. Circulation 1973; 48: 619-623
    CrossrefPubMedGoogle Scholar
  • 24 Szczeklik A, Gryglewski RJ, Musial J, Grodzinska L, Serwonska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemostas 1978; 40: 66-74
    PubMedGoogle Scholar
  • 25 Hughes A, Daunt S, Vass G, Wickes J. In vivo platelet activation following myocardial infarction and acute coronary ischemia. Thromb Haemostas 1982; 48: 133-135
    PubMedGoogle Scholar
  • 26 Pengo V, Boschello M, Prandoni P, Schiavon R, Bellotto F, Schivazappa L, Dalla Volta S. Enhanced “in vitro” release of platelet alfa-granules after acute myocardial infarction (AMI). Thromb Haemostas 1985; 54: 544-546
    PubMedGoogle Scholar
  • 27 Jaffe AS, Lee RG, Perez JE, Geltman EM, Wilner GB, Sobel BE. Lack of elevation of platelet factor IV in plasma from patients with myocardial infarction. J Am Coll Cardiol 1984; 4: 653-659
    CrossrefPubMedGoogle Scholar
  • 28 Meade TW, Vickers MV, Thompson SG, Sterling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985; 290: 428-432
    CrossrefPubMedGoogle Scholar
  • 29 Greer IA, Walker JJ, McLaren M, Calder AA, Forbes CD. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. Thromb Haemostas 1985; 54: 480-484
    PubMedGoogle Scholar
  • 30 Callahan KS, Johnson AR, Campbell WB. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets. Circulation 1985; 71: 1237-1246
    CrossrefPubMedGoogle Scholar
  • 31 Dale J, Landmark KH, Myhre E. The effects of nifedipine, a calciumantagonist, on platelet function. Am Heart J 1983; 105: 103-105
    CrossrefPubMedGoogle Scholar
  • 32 Ring ME, Corrigan Jr JJ, Fenster PE. Effects of oral diltiazem on platelet function: alone and in combination with “low dose” aspirin. Thromb Res 1986; 44: 391-400
    CrossrefPubMedGoogle Scholar
  • 33 Born GV R, Hardesty RM. Platelets. In: 2. ed Biggs R. (ed) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell; Oxford: 1976: 180
    Google Scholar
  • 34 Meade TW, Chakrabarti R, Haines AP, North WRS, Sterling Y, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054
    PubMedGoogle Scholar
  • 35 Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
    CrossrefPubMedGoogle Scholar
  • 36 O’Connor NT J, Cederholm-Williams S, Copper S, Cotter L. Hypercoagulability and coronary artery disease. Br Heart J 1984; 52: 614-616
    CrossrefPubMedGoogle Scholar
  • 37 Meade TW, Chakrabarti R, Haiones AP, North WR S, Sterling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-156
    CrossrefPubMedGoogle Scholar
  • 38 Baker IA, Eastham R, Elwood PC, Etherington M, O’Brien JR, Sweetnam PM. Hemostatic factors associated with ischemic heart disease in men aged 45—64 years. The Speedwell study. Br Heart J 1982; 47: 490-494
    PubMedGoogle Scholar
  • 39 Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714
    CrossrefPubMedGoogle Scholar
  • 40 Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T. Longterm treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985; 5: 1428-1437
    CrossrefPubMedGoogle Scholar
  • 41 Mehrotra TN, Mitai HS, Singh VS, Kumar A, Sinha AK, Raka MS. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in angina pectoris before and after propranolol treatment. J Assoc Physicians India 1983; 31: 641-643
    PubMedGoogle Scholar
  • 42 Caimi G, Catania A, Frazzetta F, Copobianco D, Sarno A. The behaviour of the haemorheological determinants and their trends during beta-blocker treatment. Jpn Heart J 1983; 24: 723-729
    CrossrefPubMedGoogle Scholar